Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 12, 2017

View Archived Issues

CFFT award supports Aridis' development of Panaecin for patients with cystic fibrosis

AMAG Pharmaceuticals enters licensing agreement with Palatin Technologies for bremelanotide

Aduro Biotech, Merck & Co. to investigate CRS-207 plus pembrolizumab in gastric cancer

ProNAi Therapeutics changes name to Sierra Oncology, transfers phase I trials of SRA-737

Phase I trial begins for Moderna's mRNA-based Zika vaccine candidate

DSMB recommends continuation of Evgen's phase II trial of SFX-01 in subarachnoid hemorrhage

IACTA acquires North American rights to Nanomerics' NM-133 for dry eye

Gemcabene shows efficacy for NASH in preclinical proof-of-concept study

LegoChem and Takeda enter research licensing agreement to evaluate next-generation ADC candidates

Abivax to receive funding to strengthen antiviral platform

G1 Therapeutics begins three breast cancer drug programs

Gilead's Vemlidy approved for HBV infection in E.U.

FDA grants orphan drug status to Sangamo Therapeutics' SB-318

Targeted knockdown of SMN-AS1 as a potential new SMA therapeutic strategy

FDA issues complete response letter for Tesaro's NDA for intravenous rolapitant

Genomics-based drug repurposing identifies sitagliptin as potential antiepileptic drug

FDA grants QIDP and fast track designations to VivaGel in bacterial vaginosis

RedHill Biopharma's RHB-104 awarded FDA QIDP designation

Gas6-AXL pathway as a new target for development of ZIKV therapies

Bird Rock Bio cleared to begin phase I study of namacizumab

Bayer patents anticancer compounds

Takeda reports M1 PAMs for Alzheimer's disease

Kissei Pharmaceutical describes TRPM8 antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...